Mirikizumab Omvoh®
Mirikizumab is a humanised IgG4 monoclonal antibody directed against the p19 subunit of interleukin-23. The SHIKARI® Mirikizumab portfolio supports two distinct research questions: quantitative measurement of mirikizumab concentration and qualitative detection of specific anti-mirikizumab antibodies.
Why Mirikizumab is relevant to biological-drug monitoring research
Mirikizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Mirikizumab is a humanised IgG4 monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and inhibits IL-23 signalling. Source ↗
Approved Indications
EMA-authorised uses include moderately to severely active ulcerative colitis and Crohn’s disease in adults with an inadequate response, loss of response or intolerance to conventional or advanced therapy as specified in the label. EMA source ↗
IBD Regimen-Specific Exposure
FDA pharmacokinetic data provide separate induction and maintenance exposure references:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two complementary research assays
Enzyme immunoassay for the specific quantitative determination of mirikizumab in human serum and plasma, developed for concentration measurement between the Cmin and Cmax range.
Enzyme immunoassay for the qualitative determination of antibodies to mirikizumab in human serum and plasma, reported as a positive or negative result.
Kit Specifications at a Glance
| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-MIR | MIR-FD-OMV | Drug-Level Kit | Mirikizumab | ELISA | 96 | 2–8°C |
| SHIKARI® S-ATMIR | MIR-QLS-OMV | Qualitative ADA Kit | Antibodies to mirikizumab | ELISA | 96 | 2–8°C |
* Store at +4°C and refer to the current protocol supplied with the kit. Both official records list human species reactivity. Q-MIR spike recovery is 85–115%. Specifications were verified against the exact official product records.
Which kit fits your research question?
Choose the drug-concentration assay or the qualitative anti-drug-antibody assay according to the required analytical output.
Mirikizumab Literature and Product-Use Records
Ready to order, or need technical guidance?
Matrix Biotek can help identify the appropriate Mirikizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.